SARMs (selective androgen receptor modulators) are a class of drugs designed to bind the androgen receptor and switch it on in some tissues while leaving it comparatively quiet in others. The pitch is straightforward: capture the muscle-building and bone-strengthening effects of testosterone without the prostate growth, hair loss, acne, and heavy suppression that come with anabolic steroids. That is the theory people repeat. The evidence is more modest, and this guide sticks to what has actually been measured in humans.
Most of the compounds sold as SARMs were developed by pharmaceutical companies as candidate treatments for muscle wasting, osteoporosis, cancer cachexia, and age-related frailty. None has completed the full regulatory path to approval as a SARM for those uses. What is sold online today is almost entirely from the unregulated research-chemical market, not a licensed medicine.
What 'selective' really means
Steroids like testosterone act on the androgen receptor everywhere the receptor is expressed: muscle, bone, prostate, skin, scalp, liver, and the brain. SARMs are non-steroidal molecules engineered to produce a tissue-selective pattern of receptor activation. In lab and animal models, several of them do show a genuine split, more anabolic effect on muscle and bone relative to their effect on the prostate. That is the real scientific basis for the class.
The gap opens when you move from cell cultures and rodents to people. Selectivity is a matter of degree, not an on/off property, and the margins measured in humans are narrower than the marketing implies. The clearest example is suppression: because these drugs are androgen receptor agonists, the body reads them as an androgen signal and dials down its own testosterone production. That happens with the muscle-targeting SARMs in humans, which tells you the selectivity is partial, not absolute.
What the human trials found
Ostarine (enobosarm) has the most human data of any compound in this group, with several completed phase 2 trials in cancer-related muscle loss and other wasting conditions. Across those studies, participants gained lean body mass and improved some measures of physical function versus placebo at doses in the 1 to 3 mg per day range, which is well below what people take recreationally. That is a real, measured anabolic signal in humans, and it is genuinely useful evidence.
Ligandrol (LGD-4033) has a small phase 1 study in healthy young men. Over 21 days it increased lean mass and, importantly, suppressed total testosterone and sex-hormone-binding globulin in a dose-dependent way, confirming that a muscle-selective SARM still shuts down the gonadal axis. Testolone (RAD140) has essentially no published dosing trials in healthy people; its human exposure comes mostly from an early breast-cancer program and scattered case reports, several of which describe liver injury.
The honest summary is that a couple of these compounds can add lean mass in humans over short study windows, but the trials are small, short, and mostly conducted in patient populations rather than healthy lifters. Effect sizes at study doses are meaningful but not dramatic, on the order of one to a few kilograms of lean mass over weeks.
Where the evidence runs out
- Long-term safety is unknown. The longest controlled human exposures are measured in weeks to a few months. There are no multi-year outcome data in healthy people, so nobody can quote you a real long-term risk profile.
- Cardiovascular and lipid effects are under-characterised. Suppression of HDL cholesterol is commonly reported, but hard endpoints like heart attacks and strokes have never been studied in this population.
- Fertility recovery timelines after heavy or stacked use are anecdotal, not established.
- The recreational doses people actually use are far above trial doses, so even the good human data does not describe how these drugs behave in real-world use.
The grey-market problem
Because SARMs are sold as research chemicals rather than medicines, what is in the bottle is frequently not what the label says. Independent testing programs and published analyses have repeatedly found that a large share of products sold as SARMs contained the wrong compound, no active compound at all, an unlisted second drug, or an anabolic steroid substituted in. Doses have varied wildly from what was printed. This is not a rare mishap; it is a documented, systemic feature of the market.
That matters for two reasons. First, you cannot reason about risk if you do not know what you are taking. Second, contamination is the most likely explanation for a chunk of the alarming case reports, someone may have taken a mislabelled product spiked with something more toxic. Athletes should also note that SARMs are banned in and out of competition by WADA, and contamination has caused positive tests in people who believed they were taking something else.
Not the same as a SERM
Worth clearing up a common confusion: SARMs are not the same thing as SERMs (selective estrogen receptor modulators) such as tamoxifen or clomifene. SERMs act on the estrogen receptor and are the standard tools for restarting natural testosterone production after suppression. They come up constantly in SARM discussions because they are used for recovery afterwards, but they are a different drug class with a different target.
Bottom line
SARMs are real drugs with a real, partial basis for their selectivity claim, and a small amount of genuine human evidence shows a couple of them add lean mass over short periods. But the class is oversold: selectivity is incomplete, suppression is real, the long-term human safety data simply does not exist, and the products themselves are frequently mislabelled or contaminated. Treat any risk claim in either direction, safe or catastrophic, as under-evidenced. This is reference information, not medical advice.